Animal Biotechnology Market Size, Share, Growth, and Industry Analysis, By Type (Drugs,Vaccinations,Diagnostic Tests,Genetic and Reproductive Products,Others), By Application (Diagnosis of Animal Diseases,Treatment of Animal Diseases,Preventive Care of Animals,Development of Animal Pharmaceuticals,Food Safety and Drug Development,Others), Regional Insights and Forecast to 2035

Animal Biotechnology Market Overview

The global Animal Biotechnology Market size is projected to grow from USD 28746.21 million in 2026 to USD 31057.41 million in 2027, reaching USD 57655.33 million by 2035, expanding at a CAGR of 8.04% during the forecast period.

The Animal Biotechnology Market encompasses advanced biologics, genetic and reproductive technologies, diagnostics, vaccines, and other biotech tools applied to companion and livestock animals. In 2024, the global animal biotechnology market size was estimated at USD 28.9 billion, with biologics constituting ~34 % of that figure, and diagnostic tests ~28 %. Preventive care and treatment combined accounted for ~74 % of application share, while reproductive technologies held ~12 %. Livestock animals comprised ~63 % of market share by value, and companion animals ~37 %. In the Animal Biotechnology Market Research Report context, top players invest > 15 % of revenue into R&D annually, deploying over 450 registered patents in 2023.

The U.S. animal biotechnology market is significant: in 2024, U.S. contribution to the global animal biotech market was estimated at USD 7,073.8 million, representing ~25 % share. Biologics lead product types in the U.S., capturing ~35 % share, with genetic & reproductive technologies ~18 %. The U.S. accounts for ~30 % of global veterinary diagnostic test consumption via biotech methods. Domestic patent filings in 2023 exceeded 210 biotech applications in veterinary fields. The U.S. regulatory environment enabled commercial deployment of over 12 transgenic animal trials in 2022–2024, supporting the Animal Biotechnology Market Outlook and industry innovation pipeline.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 38 % of veterinary firms cite rising incidence of zoonotic and animal diseases as primary impetus.
• Major Market Restraint: 29 % of smaller biotech firms report regulatory compliance cost as a barrier to product launch.
• Emerging Trends: 31 % of new animal biotech products incorporate CRISPR or gene-editing modules.
• Regional Leadership: North America held ~35.7 % share of the global animal biotechnology market in 2025.
• Competitive Landscape: Top 5 animal biotech firms command ~22 % of global market value share.
• Market Segmentation: Biologics and diagnostics together represent ~62 % of product value in animal biotechnology.
• Recent Development: In 2023–2025, ~22 % of new vaccine launches used mRNA or vector-based platforms for animals.

Animal Biotechnology Market Latest Trends

In recent years, the Animal Biotechnology Market Trends have centered on gene editing (CRISPR), diagnostic platform miniaturization, and vaccine innovation. As of 2024, ~31 % of newly introduced programs leverage CRISPR or gene editing for disease resistance in livestock or companion animals. Diagnostic test kits using point-of-care molecular assay methods constituted ~28 % of diagnostic revenue share. The shift to multiplex diagnostic panels is rising: ~14 % of new assays launched in 2024 test for 3+ pathogens simultaneously. Vaccine innovation accelerates: ~22 % of new animal biotech vaccine products in 2024 used viral vector or mRNA approaches. Companion animal biotech is growing faster: ~8 % higher year-on-year in 2023–2024 compared to livestock segment. The field of precision livestock farming (PLF) is contributing: ~45 public computer vision datasets exist for cattle, swine, poultry; nearly half focus on cattle, supporting biotech phenotyping. In vitro cell line development for livestock disease models expanded ~19 % in 2024. Regional expansions continue: Asia-Pacific biotech installations rose ~27 % in 2024 over 2022 levels. The Animal Biotechnology Market Forecast anticipates continued blend of diagnostics, vaccines, genetic tools, and data-driven integration.

Animal Biotechnology Market Dynamics

Global Animal Biotechnology Market, valued at USD 26,607 million, is characterized by a dynamic mix of technological progress, regulatory shifts, and increased demand for animal health innovation. The sector’s growth is propelled by rising livestock production, the surge in zoonotic diseases, and adoption of genetic modification tools. Approximately 42 % of market activity in 2025 is driven by vaccine and diagnostic product innovation, while 31 % is linked to genomic and reproductive biotechnology applications.

DRIVER

"Rising prevalence of animal diseases and demand for improved diagnostics and therapeutics"

A primary growth driver is the increasing burden of animal diseases—infectious, parasitic, and emerging zoonoses—coupled with rising demand for advanced diagnostics and targeted therapeutics. In 2023, globally over 6 million cases of animal disease outbreaks (e.g., foot and mouth, avian influenza) were reported across livestock populations. Companion animal disease prevalence (e.g. canine cancers, feline viruses) rose ~11 % annually in developed markets. Over 38 % of veterinary biotechnology spending is directed at diagnostics and vaccines addressing infectious disease. The adoption of gene-editing for resistance breeding in livestock has increased livestock survival rates by 8–12 % in pilot herds. Many biotech firms report that ~42 % of new project pipelines are directed toward novel vaccines and diagnostics. Demand for food safety also catalyzes development of diagnostic tools: ~25 % of biotech R&D budgets now target residue detection and zoonotic biomarkers. As animal protein demand grows, disease control pressure increases, underpinning growth in the Animal Biotechnology Market.

RESTRAINT

" High regulatory barriers, long approval cycles, and ethical concerns"

Significant restraints include regulatory complexity, long biologic approval cycles, and ethical debates over genetic modifications. In many jurisdictions, animal biotech products require multi-stage field trials spanning 3–5 years. ~29 % of biotech startups cite regulatory costs and delays as major adoption barriers. Ethical or social resistance to transgenic animals affects ~15 % of proposed projects. Intellectual property and biosafety regulations sometimes require multi-agency approvals in ~13 regulator zones for cross-border trials. In companion animal markets, consumer skepticism delays uptake: ~18 % of pet owners express unease about gene-modified therapies. Some regions enforce strict bans on certain recombinant animal constructs—~11 national jurisdictions restrict GMO animal therapeutics. These friction points slow product commercialization and enlarge barrier to entry, restraining Animal Biotechnology Market Growth in less regulated or ethically conservative markets.

OPPORTUNITY

" Integration of biotech with data, precision breeding, and personalized animal therapeutics"

Key opportunities lie in combining biotechnology tools with data analytics, precision breeding, and tailored therapies. ~31 % of new pipelines integrate genomics data, phenotyping, and AI for breeding decisions. Companion animal biotech can emulate human precision medicine trends: ~9 % of new therapeutic programs in 2024 applied personalized subtypes for canine oncology. Gene-editing to enhance feed efficiency or disease resistance is being explored in ~14 pilot livestock herds, with productivity gains of 6–9 %. Diagnostics-as-a-service models are emerging: ~17 % of companies now offer subscription models for molecular diagnostics in veterinary clinics. Integration with livestock management platforms supports real-time interventions. Emerging vaccines combining antigen + adjuvant design with host genetic data were ~12 % of new launches. CRISPR-based pathogen detection systems that provide both diagnosis and gene editing are entering ~8 % of research pipelines. These directions represent strong Animal Biotechnology Market Opportunities for firms scaling integrated platforms rather than isolated products.

CHALLENGE

"High R&D costs, scalability, and adoption by traditional veterinary sectors"

A critical challenge is the capital intensity and technological risk of biotech R&D. Approximately 29 % of animal biotech ventures fail in early-stage trials due to safety or efficacy issues. Scale-up to commercial manufacturing requires bioreactors, purification, and QA infrastructure—~22 % of projects lack capacity to scale. Many veterinary markets remain historically conservative: ~17 % of clinics are slow to adopt novel biotech diagnostics or therapies. Pricing constraints in livestock sectors limit margin: ~19 % of biotech firms report inability to charge premium prices in large agile farms. Field variability in animal genetics and environment causes ~12 % of trial variability in efficacy results. Delivery logistics for biologics (cold chain, injection) cause ~14 % of failures in remote regions. Veterinary education gaps also slow adoption: ~11 % of practitioners report unfamiliarity with genetic tools. These challenges restrain broad commercialization, particularly in emerging markets, limiting the pace of Animal Biotechnology Market Expansion.

Animal Biotechnology Market Segmentation

The Animal Biotechnology Market is segmented by Type (Drugs, Vaccinations, Diagnostic Tests, Genetic & Reproductive Products, Others) and by Application (Diagnosis of Animal Diseases, Treatment of Animal Diseases, Preventive Care, Development of Animal Pharmaceuticals, Food Safety & Drug Development, Others). In 2024, vaccines and biologic drugs combined comprised ~34 % of market value, diagnostics ~28 %, genetic & reproductive ~12 %, and other types ~16 %. Preventive care and treatment dominate application segments (~74 % share), while drug development and food safety represent ~18 %. These segments drive the Animal Biotechnology Market Size and Animal Biotechnology Market Share dynamics across regions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Drugs: The Drugs segment (therapeutic agents developed through biotech) formed ~12 % of market value in 2024. These include recombinant proteins, monoclonal antibodies, growth factors, and enzyme therapies for animals. Over 85 therapeutic biotech drug programs were in development in 2023 across companion species and livestock. In the U.S., ~22 biotech drugs were approved or in late-stage trials as of 2024. The drugs segment particularly serves applications in chronic disease management in pets and production diseases in livestock. Scalability and safety are key: ~14 % of drug trials fail in advanced phases. Nonetheless, this type forms a strategic growth lever in Animal Biotechnology Market Growth.

Vaccinations: Vaccines represent the largest single type share (~28–34 %) in animal biotechnology. In 2024, over 250 novel vaccine candidates (viral, bacterial, vector, mRNA) were in various development stages. In one year, ~18 million doses of biotech-derived veterinary vaccines (e.g. recombinant, viral vectored) were distributed globally. In developing markets, ~30 % of livestock farms now require biotech vaccines versus traditional ones. Companion animal vaccine adoption of biotech subunit vaccines expanded ~22 % in 2023–2024. Vaccine type retains strong dominance in Animal Biotechnology Market Share due to scale and preventive importance.

Diagnostic Tests: The Diagnostic Tests type holds ~28 % share of the animal biotechnology market in 2024. Rapid molecular diagnostics, point-of-care PCR, ELISA, multiplex panels, and next-generation sequencing-based tests are included. In 2024, ~14 million diagnostic kits were sold for veterinary use globally. Point-of-care molecular tests grew ~23 % year-on-year in 2024. Many veterinary clinics now carry one or more biotech diagnostic tools—~32 % of mid-tier clinics in developed markets. Diagnostic type is among the fastest evolving segments in the Animal Biotechnology Market Trends.

Genetic & Reproductive Products: Genetic & Reproductive Products (including gene editing, embryo transfer, cloning, genomic selection) made up ~12 % of value in 2024. Over 120 genomic breeding programs were operational globally in 2023, involving cattle, swine, poultry. In 2024, ~65 pilot CRISPR-edited livestock herds were active in field trials. Assisted reproductive services (ART) are used in ~22 % of elite breeding stock. Companion animal genetic screening kits and reproductive biotech (e.g. in vitro fertilization) contributed ~11 % of product count. This type is central to long-term Animal Biotechnology Market Opportunities.

Others: The Others type (feed additives, bioactive supplements, novel biomaterials, research reagents) contributed ~16 % of market value in 2024. Examples include enzyme supplements, probiotic biotechnologies, and biomaterials for diagnostics. In 2024, ~8 million units of biotech feed additive supplements were utilized in livestock operations. Research reagent sales (e.g. biotech kits, gene editing reagents) in animal biotech labs represented ~12 % of unit demand. Though smaller, this type supports innovation and cross-market synergies in the Animal Biotechnology Market Outlook.

BY APPLICATION

Diagnosis of Animal Diseases: The Diagnosis application held ~24 % share in 2024, with growing penetration of molecular diagnostics. ~14 million diagnostic test units were used globally in veterinary settings in 2024. Clinics in the U.S. accounted for ~28 % of diagnostic test usage; ~22 % of livestock farms employ on-site biotech diagnostics. Multiplex panels (3+ pathogen targets) constitute ~14 % of diagnostics product mix. Diagnosis application is growing rapidly within the Animal Biotechnology Market Trends.

Treatment of Animal Diseases: Treatment application (~22 % share) includes therapeutic biotech drugs and biologics used to treat infections, cancers, metabolic diseases in animals. Over 75 ongoing clinical trials for biotech therapeutics in animals were active in 2023. Companion animal trials dominate (~60 %). In 2024, ~1.5 million treatments using biotech therapeutics were administered worldwide in veterinary settings. Treatment is integral to the Animal Biotechnology Market Growth pipeline.

Preventive Care of Animals

The Preventive Care application (vaccines, prophylactic biologics) occupies ~28 % share. In 2024, ~18 million vaccine doses with biotech components were deployed. Preventive care is standard in ~70 % of commercial poultry and swine operations. In companion animals, ~45 % of pet owners request advanced vaccine protocols. Preventive care stands as a foundation of Animal Biotechnology Market Share.

Development of Animal Pharmaceuticals: The Drug Development application (R&D, biotech discovery) accounts for ~12 % share. Over 450 biotech R&D programs targeted at veterinary medicine were active in 2023. Investment in pipeline technologies (gene therapy, RNA, etc.) rose ~20 % in 2024. This application underpins long-term innovation in Animal Biotechnology Market Opportunities.

Food Safety and Drug Development: This application (~10 % share) covers biotech tools for ensuring safe animal-derived food, testing, residue detection, biomarker development. In 2024, ~6 million assays applied for food safety in processing systems used biotech platforms. Drug residue screening in meat, milk, eggs used ~18 % of biotech diagnostic capacity. This application strengthens synergy between biotech and food industry demands.

Others: “Others” covers research, biomaterials, environment, ancillary services (~4 %). In 2024, ~3 million units of ancillary biotech products (e.g. reagents, custom services) were sold for veterinary or research use. Though small, this application supports ecosystem expansion in Animal Biotechnology Market Insights.

Regional Outlook for the Animal Biotechnology Market

Regional performance: North America ~35.7 % share, Europe ~28 %, Asia-Pacific ~25 %, Middle East & Africa ~11 % in 2025 estimates. Growth dynamics: Asia-Pacific reported ~27 % year-on-year expansion in deployed biotech programs 2023–2024, while North America added ~18 % new biotech product launches. Each region drives distinct niches: North America leads biologics and diagnostics, Europe emphasizes regulatory platforms, Asia-Pacific accelerates vaccine & gene editing adoption, MEA focuses on livestock biotech upgrades.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds about 35.7 % share of the global animal biotechnology market in 2025, estimated value ~USD 10.3 billion (using global ~USD 28.9 billion base). The U.S. is the epicenter, contributing over USD 7,073.8 million in 2024, representing ~25 % global share. In 2023–2024, the region launched over 85 new biotech animal health products, with biologics capturing ~34 % share of regional value. Diagnostics sales surged ~23 % year-on-year in 2024. North American labs conducted ~150,000 veterinary molecular assays in 2024. Regulatory support is strong: ~18 regulatory approvals for transgenic or biotech animal trials were granted 2022–2024. Biotech breeding and gene-editing pilot herds in U.S. and Canada numbered ~75. The region has ~62 % of global registered veterinary biotech patents. Bioinformatics and data integration platforms are used by ~28 % of veterinary networks. Assisted reproductive biotech services expanded ~12 %. The North America region remains a central base for the Animal Biotechnology Market Report, Animal Biotechnology Market Trends, and Animal Biotechnology Market Forecast.

The North America Animal Biotechnology Market is estimated at USD 9,312 million in 2025, holding 35.0 % of global share, and is projected to reach USD 18,550 million by 2034, expanding at a CAGR of 8.06 %.

North America – Major Dominant Countries in the Animal Biotechnology Market

• United States: Market size USD 6,580 million (2025), share 70.7 %, CAGR 8.08 %; strong leadership in genetic modification and vaccine development programs with 120 active biotech patents.
• Canada: Market size USD 1,320 million (2025), share 14.1 %, CAGR 8.02 %; rapidly growing biotech diagnostic manufacturing hub with over 40 registered R&D projects.
• Mexico: Market size USD 910 million (2025), share 9.7 %, CAGR 8.05 %; expanding livestock vaccine adoption and regional biotech collaborations with U.S. firms.
• Cuba: Market size USD 250 million (2025), share 2.7 %, CAGR 8.00 %; state-backed biotech innovation and animal vaccine research expansion.
• Puerto Rico: Market size USD 252 million (2025), share 2.8 %, CAGR 7.96 %; development of export-based animal drug production facilitie

EUROPE

Europe commands roughly 28 % of the global animal biotechnology market in 2025, valuing ~USD 8.1 billion. Germany, France, UK, Italy, Spain account for ~55 % of European value. In 2023–2024, European animal biotech firms filed ~95 patent applications. EU regulatory frameworks require ~15 months of multi-nation approval for transgenic constructs. European livestock biotech programs number ~45 pilots. Diagnostics adoption grew ~19 %. Bioethical and GMO oversight impacted ~14 national jurisdictions. The biotech vaccine rollout in European poultry increased ~21 %. Genomic selection programs in EU dairy herds cover ~28 % of elite breeds. The European region is central to Animal Biotechnology Industry Analysis and Market Insights focused on regulatory harmonization and public acceptance.

The Europe Animal Biotechnology Market is valued at USD 7,370 million in 2025, contributing 27.7 % global share, and is projected to reach USD 14,860 million by 2034, growing at a CAGR of 8.01 %.

Europe – Major Dominant Countries in the Animal Biotechnology Market

• Germany: Market size USD 1,920 million (2025), share 26.0 %, CAGR 8.02 %; leader in veterinary molecular biology tools and vaccine formulation exports.
• France: Market size USD 1,430 million (2025), share 19.4 %, CAGR 8.01 %; expanding national biotech farms under sustainable livestock innovation frameworks.
• United Kingdom: Market size USD 1,220 million (2025), share 16.5 %, CAGR 8.04 %; robust companion animal biotech R&D ecosystem.
• Italy: Market size USD 980 million (2025), share 13.3 %, CAGR 7.98 %; high investment in livestock breeding genetics and diagnostics.
• Spain: Market size USD 890 million (2025), share 12.1 %, CAGR 8.00 %; increasing adoption of biotech vaccines in poultry and swine industries.

ASIA-PACIFIC

Asia-Pacific accounts for ~25 % share (~USD 7.2 billion in 2025). China and India dominate ~60 % of regional value. In 2023–2024, Asia launched ~120 new biotech animal health products—vaccines ~45 %. Diagnostic adoption in Asia rose ~27 % year-on-year. Pilot gene-editing herds in China numbered ~40, India ~20. Asia’s biotech R&D investment rose ~22 %. Vaccine manufacturing capacity expansions in Asia increased ~32 %. Companion animal biotech growth outpaced livestock in Southeast Asia (~8 % faster). Regional regulatory approvals accelerated: ~14 programs cleared in China, South Korea, Japan in 2024. Asia is critical in the Animal Biotechnology Market Growth for scaling biotech access in emerging markets.

The Asia Animal Biotechnology Market is forecast at USD 6,780 million in 2025, representing 25.5 % of global market share, expected to reach USD 13,890 million by 2034, growing at a CAGR of 8.08 %.

Asia – Major Dominant Countries in the Animal Biotechnology Market

• China: Market size USD 3,420 million (2025), share 50.4 %, CAGR 8.10 %; dominant in livestock biotech and vaccine export capacity.
• India: Market size USD 1,680 million (2025), share 24.8 %, CAGR 8.11 %; growing biotech drug research base with > 45 startups focusing on veterinary biosciences.
• Japan: Market size USD 830 million (2025), share 12.2 %, CAGR 8.03 %; advanced biotech diagnostics for companion animals.
• South Korea: Market size USD 470 million (2025), share 6.9 %, CAGR 8.07 %; strong R&D collaboration in CRISPR-based animal genetics.
• Indonesia: Market size USD 380 million (2025), share 5.6 %, CAGR 8.04 %; accelerating biotech vaccine manufacturing expansion.

MIDDLE EAST & AFRICA

MEA represents ~11 % share (~USD 3.2 billion) in 2025. In 2023–2024, MEA registered ~20 biotech product launches focused on livestock vaccines and diagnostics. GCC countries deployed ~15 national animal biotech programs. South Africa and Egypt led regional biotech adoption; ~12 pilot gene-edited breeding projects exist. Diagnostic kit usage in MEA veterinary sectors rose ~14 %. Regulatory harmonization remains a challenge in ~10 national jurisdictions. Biotech adoption in pastoral zones is emerging with ~8 mobile diagnostic labs deployed. MEA growth supports Animal Biotechnology Market Outlook for emerging livestock sectors.

The Middle East and Africa Animal Biotechnology Market is valued at USD 3,145 million in 2025, accounting for 11.8 % of global share, and is forecast to reach USD 6,060 million by 2034, with a CAGR of 8.02 %.

Middle East and Africa – Major Dominant Countries in the Animal Biotechnology Market

• United Arab Emirates: Market size USD 870 million (2025), share 27.6 %, CAGR 8.03 %; heavy focus on genetic livestock improvement and animal vaccine manufacturing.
• Saudi Arabia: Market size USD 780 million (2025), share 24.8 %, CAGR 8.02 %; biotech R&D integration with food security strategies.
• South Africa: Market size USD 530 million (2025), share 16.9 %, CAGR 8.00 %; government-sponsored veterinary genomics projects for cattle and poultry.
• Egypt: Market size USD 470 million (2025), share 14.9 %, CAGR 8.01 %; strong regional diagnostics manufacturing expansion.
• Nigeria: Market size USD 390 million (2025), share 12.4 %, CAGR 8.04 %; biotech disease prevention and livestock productivity programs expanding nationwide.

List of Top Animal Biotechnology Companies

• Merck & Inc.
• Ouro Fino Saude Animal
• Phibro Animal Health
• IDEXX L:aboratories
• Neogen
• Animal Biotech
• Sequent Scientific Ltd
• Virbac Inc.
• Zoetis
• Elanco
• Dechra Pharmaceuticals
• Boehringer Ingelheim International GmbH
• Kyoritsu Seiyaku Corporation
• Bayer AG
• Santa Cruz Biotechnology

Zoetis: estimated ~9.5 % share of global animal biotechnology market value, leading biologics and diagnostics.

Merck & Inc. (Merck Animal Health): holds ~8.2 % share globally in animal biotech product development and veterinary biologics.

Investment Analysis and Opportunities

Investment activity in animal biotechnology is accelerating, as pharmaceutical, agritech, and veterinary firms expand biotech pipelines. In 2023–2024, disclosed investments exceeded USD 1.2 billion into animal biotech startups, gene-editing platforms, and diagnostic scale-ups. Over 60 new animal biotech funding rounds were closed in that period. Approximately 27 venture capital deals targeted companion-animal biotech, reflecting growing premium market interest. Infrastructure expansion: 12 new biologics manufacturing facilities were announced globally to support veterinary biotech production. In livestock-rich countries, governments allocated funding for national biotech livestock programs—India, China, Brazil invested in ~5 consortia projects each. Partnerships proliferate: ~18 collaborations between breed companies and biotech firms were formed in 2024 to commercialize disease-resistant lines. Diagnostic network expansions saw ~22 new veterinary labs adopt biotech molecular platforms. Investment in digital infrastructure, data platforms, and animal health informatics accounted for ~15 % of the total spend. The Animal Biotechnology Market Opportunities center on scaling gene-editing, expanding diagnostic reach, integrating biotech with precision farming platforms, and leveraging companion animal therapy premiums in wealthier markets.

New Product Development

Recent innovations in animal biotechnology over 2023–2025 reflect advances in molecular assays, gene editing, and vaccine design. In 2024, ~22 % of new vaccines launched for livestock employed viral vector or mRNA platforms rather than traditional inactivated approaches. ~31 % of new biotech diagnostic assays introduced are multiplex molecular panels testing 5+ pathogens simultaneously. Gene-editing projects targeted traits such as disease resistance, feed efficiency, and low methane in cattle: ~15 pilot CRISPR-edited herds were field-tested. Companion animal biotech launched new monoclonal antibody therapies: ~8 new therapeutic products for canine cancers emerged in 2024. Genetic screening kits for livestock health markers increased ~19 %. A biopharma company introduced recombinant growth hormone alternative for fish species—deployed in ~1.5 million juvenile fish stocks. Another new product allowed rapid pen-side viral detection in swine—~120,000 kits sold in pilot countries in 2024. Reproductive biotech advanced embryo culture media optimization: ~14 improved media formulations used in ~25,000 embryo transfers. These innovations push forward the Animal Biotechnology Market Trends of integrated diagnostics, gene editing, and advanced therapeutics.

Five Recent Developments

• In 2023, Merck Animal Health announced a collaboration with a CRISPR firm to develop gene-edited disease-resistant pigs, targeting deployment in 8 pilot herds.
• In 2024, Zoetis launched a multiplex molecular diagnostic panel for five bovine respiratory pathogens, distributing ~500,000 test kits globally.
• In 2024, a biotech firm introduced an mRNA vaccine for canine viral disease, with 30,000 doses administered in trial rollouts across three countries.
• In 2025, a startup commercialized a pen-side disease detection device for poultry, deploying ~100,000 units in Southeast Asia.
• In early 2025, a joint venture in Brazil launched genome-edited cattle focused on lower methane emissions and improved feed conversion, enrolling ~1,200 heads in field trials.

Report Coverage of Animal Biotechnology Market

The Animal Biotechnology Market Report presents detailed coverage of product types (Drugs, Vaccinations, Diagnostics, Genetic & Reproductive, Others) and applications (Diagnosis, Treatment, Preventive Care, Drug Development, Food Safety, Others). It includes Animal Biotechnology Market Size estimates (e.g. USD 28.9 billion base) and projections in unit and value terms. The Animal Biotechnology Market Analysis provides segmentation breakdowns, adoption trends, regulatory environments, and competitive mapping. Animal Biotechnology Market Trends chapters emphasize CRISPR, mRNA vaccines, multiplex diagnostics, precision breeding, and integration with digital platforms. The Animal Biotechnology Market Forecast offers regional and country forecasts through 2034, aligned with adoption curves. Animal Biotechnology Market Insights cover drivers (disease burden, protein demand, tech advancement), restraints (regulation, cost, ethics), and challenges (scaling, adoption). The Animal Biotechnology Market Opportunities section highlights gene-editing, companion animal therapeutics, diagnostics expansion, and subscription models. The report also catalogs leading companies, their biotech pipelines, partnerships, R&D investment, and market share (Zoetis ~9.5 %, Merck ~8.2 %). Moreover, it covers regulatory landscapes, patent trends, distribution channels, adoption hurdles, and disease landscape analysis, making this Animal Biotechnology Market Report a strategic resource for biotech firms, animal health companies, investors, and policy stakeholders.

Animal Biotechnology Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 28746.21 Million in 2026
Market Size Value By	USD 57655.33 Million by 2035
Growth Rate	CAGR of 8.04% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Drugs Vaccinations Diagnostic Tests Genetic and Reproductive Products Others By Application : Diagnosis of Animal Diseases Treatment of Animal Diseases Preventive Care of Animals Development of Animal Pharmaceuticals Food Safety and Drug Development Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample